Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer.


Journal

Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 30 04 2023
accepted: 10 11 2023
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 2 2 2024
Statut: epublish

Résumé

To maximize the therapeutic ratio, it is important to identify adverse prognostic features in men with prostate cancer, especially among those with intermediate risk disease, which represents a heterogeneous group. These men may benefit from treatment intensification. Prior studies have shown pretreatment mpMRI may predict biochemical failure in patients with intermediate and/or high-risk prostate cancer undergoing conventionally fractionated external beam radiation therapy and/or brachytherapy. This study aims to evaluate pretreatment mpMRI findings as a marker for outcome in patients undergoing stereotactic body radiation therapy (SBRT). We identified all patients treated at our institution with linear accelerator based SBRT to 3625 cGy in 5 fractions, with or without androgen deprivation therapy (ADT) from November 2015 to March 2021. All patients underwent pretreatment Magnetic Resonance Imaging (MRI). Posttreatment Prostate Specific Imaging (PSA) measurements were typically obtained 4 months after SBRT, followed by every 3 to 6 months thereafter. A 2 sample One hundred twenty-three men were included in the study. Pretreatment MRI variables including median diameter of the largest intraprostatic lesion, median number of prostate lesions, and median maximal PI-RADS score, were each predictive of PSA nadir and time to PSA nadir ( Our experience shows the significant ability of mpMRI for predicting PSA outcome in prostate cancer patients treated with SBRT with or without ADT. Since PSA nadir has been shown to correlate with biochemical failure, this information may help radiation oncologists better counsel their patients regarding outcome after SBRT and can help inform future studies regarding who may benefit from treatment intensification with, for example, ADT and/or boosts to dominant intraprostatic lesions.

Identifiants

pubmed: 38304110
doi: 10.1016/j.adro.2023.101408
pii: S2452-1094(23)00236-1
pmc: PMC10831170
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101408

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Kareem Rayn (K)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Israel Deutsch (I)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Brian Jeffers (B)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Albert Lee (A)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Elizaveta Lavrova (E)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Matthew Gallitto (M)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Mark Mayeda (M)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.
Department of Radiation Oncology, The Queen's Health System, Honolulu, Hawaii.

Mark Hwang (M)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.
Department of Radiation Oncology, UW Health Cancer Center at Proealth Care, Waukesha, Wisconsin.

James Yu (J)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.
Connecticut Radiation Oncology, PC, Hartford, Connecticut.

Catherine Spina (C)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Lawrence Koutcher (L)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Classifications MeSH